Humulin Regular injection solution 100IU / ml, 3 ml No. 5

• Diabetes mellitus in the presence of indications for insulin therapy;

• newly diagnosed diabetes mellitus;

• pregnancy with type 2 diabetes mellitus (non-insulin dependent).

The dose is determined by the doctor individually, depending on the level of glycemia.

The drug should be administered subcutaneously, intravenously, possibly intramuscularly.

S / c the drug is injected into the shoulder, thigh, buttocks or abdomen. The injection site must be alternated so that the same site is used no more than about 1 time / month.

When administered subcutaneously, care must be taken to avoid entering the blood vessel. After injection, do not massage the injection site. Patients should be trained in the correct use of insulin delivery devices.

Rules for the preparation and administration of the drug

Humulin Regular cartridges and vials do not require resuspension and can only be used if their content is a clear, colorless liquid without visible particles.

Check cartridges and vials carefully. Do not use the drug if it contains flakes, if hard white particles adhere to the bottom or walls of the bottle, creating the effect of a frosty pattern.

The design of the cartridges does not allow mixing their contents with other insulins directly in the cartridge itself. Cartridges are not refillable.

The contents of the vial should be drawn into an insulin syringe corresponding to the concentration of insulin injected, and the required dose of insulin should be administered as directed by the doctor.

When using cartridges, follow the manufacturer's instructions for cartridge refilling and needle attachment. The drug should be administered in accordance with the instructions of the manufacturer of the syringe pen.

Using the outer needle cap, unscrew the needle immediately after insertion and safely discard. Removing the needle immediately after injection ensures sterility, prevents leakage, air ingress and possible clogging of the needle. Then put the cap on the handle.

The needles should not be reused. Needles and pen pens must not be used by others. Use cartridges and vials until they become empty, after which they should be discarded.

Humulin Regular can be administered in combination with Humulin NPH. To do this, short-acting insulin should be drawn into the syringe first to prevent longer-acting insulin from entering the vial. It is desirable to introduce the prepared mixture immediately after mixing. To inject the exact amount of insulin of each type, you can use a separate syringe for Humulin Regular and Humulin NPH.

Always use an insulin syringe that matches the concentration of insulin you are administering.

Solution for injection is transparent, colorless.

1 ml

human insulin 100 IU

Excipients: metacresol, glycerol (glycerin), water d / i, hydrochloric acid (10% solution) and / or sodium hydroxide (10% solution) to create the required pH level.

• Hypoglycemia

• hypersensitivity to this insulin.

Clinical and pharmacological group: Human short-acting insulin

Pharmaco-therapeutic group: Short-acting insulin

pharmachologic effect

A hypoglycemic agent, short-acting insulin. Interacting with a specific receptor in the outer membrane of cells, it forms an insulin-receptor complex. By increasing the synthesis of cAMP (in fat cells and liver cells) or directly penetrating into the cell (muscles), the insulin-receptor complex stimulates intracellular processes, incl. synthesis of a number of key enzymes (including hexokinase, pyruvate kinase, glycogen synthetase).

A decrease in the concentration of glucose in the blood is due to an increase in its intracellular transport, an increase in absorption and assimilation by tissues, stimulation of lipogenesis, glycogenesis, protein synthesis, a decrease in the rate of glucose production by the liver (a decrease in the breakdown of glycogen).

The onset of action is after 30 minutes, the maximum effect is after 1-3 hours, the duration of action is 8 hours.

Pharmacokinetics

The degree of absorption depends on the route of administration (s / c, i / m), the site of administration (abdomen, thigh, buttocks), dose, concentration of insulin in the preparation. Distribution in tissues is uneven. Does not penetrate the placental barrier and into breast milk. Destroyed by insulinase, mainly in the liver and kidneys. T1 / 2 up to 10 min. It is excreted by the kidneys - 30-80%.

Side effect

Allergic reactions: urticaria, angioedema, fever, shortness of breath, decreased blood pressure.

From the endocrine system: hypoglycemia with such manifestations as pallor, increased sweating, palpitations, sleep disorders, tremors; neurological disorders; immunological cross-reactions with human insulin; an increase in the titer of anti-insulin antibodies with a subsequent increase in glycemia.

From the side of the organ of vision: transient visual impairment (usually at the beginning of therapy).

Local reactions: hyperemia, itching and lipodystrophy (atrophy or hypertrophy of subcutaneous adipose tissue) at the injection site.

Others: at the beginning of treatment, swelling is possible (disappear with continued treatment).

Application during pregnancy and lactation

During pregnancy, it is necessary to take into account a decrease in the need for insulin in the first trimester or an increase in the II and III trimesters. During and immediately after childbirth, the need for insulin can drop dramatically.

During the period of breastfeeding, the patient needs daily monitoring for several months (until the insulin requirement stabilizes).

Application for violations of liver function

With liver disease, the need for insulin may vary.

Application for impaired renal function

With kidney disease, the need for insulin may vary.

Use in elderly patients

Insulin dose adjustment is required for diabetes mellitus in patients over 65 years of age.

special instructions

The dose selection of the drug is carried out with caution in patients with previous ischemic cerebral circulation disorders and with severe forms of ischemic heart disease.
The need for insulin can change in the following cases: when switching to another type of insulin; when changing the diet, diarrhea, vomiting; when the usual volume of physical activity changes; with diseases of the kidneys, liver, pituitary gland, thyroid gland; when changing the injection site.
Insulin dose adjustment is required for infectious diseases, thyroid dysfunction, Addison's disease, hypopituitarism, chronic renal failure and diabetes mellitus in patients over 65 years of age.

The transfer of a patient to human insulin should always be strictly justified and carried out only under the supervision of a physician.

The causes of hypoglycemia can be: insulin overdose, drug replacement, skipping meals, vomiting, diarrhea, physical exertion; diseases that reduce the need for insulin (severe kidney and liver diseases, as well as hypofunction of the adrenal cortex, pituitary gland or thyroid gland), change of injection site (for example, skin on the abdomen, shoulder, thigh), as well as interactions with other drugs. A decrease in the concentration of glucose in the blood is possible when a patient is transferred from animal insulin to human insulin.

The patient should be informed about the symptoms of a hypoglycemic state, the first signs of a diabetic coma and the need to inform the doctor about all changes in his condition.

In case of hypoglycemia, if the patient is conscious, dextrose is prescribed by mouth; s / c, i / m or i / v injected glucagon or intravenous hypertonic dextrose solution. With the development of hypoglycemic coma, 20-40 ml (up to 100 ml) of 40% dextrose solution is injected intravenously, until the patient comes out of the coma.

Patients with diabetes mellitus can relieve themselves of mild hypoglycemia by eating sugar or foods high in carbohydrates (patients are advised to always have at least 20 g of sugar with them).

Alcohol tolerance in patients receiving insulin is reduced.

Influence on the ability to drive vehicles and mechanisms

The tendency to develop hypoglycemia can impair the ability of patients to drive vehicles and work with mechanisms.

Drug interactions

The hypoglycemic effect is enhanced by sulfonamides (including oral hypoglycemic drugs, sulfonamides), MAO inhibitors (including furazolidone, procarbazine, selegiline), carbonic anhydrase inhibitors, ACE inhibitors, NSAIDs (including salicylates), anabolic steroids (including stanozolol, oxandrolone, methandrostenolone), androgens, bromocriptine, tetracyclines, clofibrate, ketoconazole, mebendazole, theophylline, cyclophosphamide, fenfluramine, lithium preparations, pyridoxine, quinidine, quinine, chloroquinine.

The hypoglycemic effect is reduced by glucagon, corticosteroids, histamine H1 receptor blockers, oral contraceptives, estrogens, thiazide and 'loop' diuretics, slow calcium channel blockers, sympathomimetics, thyroid hormones, tricyclic antidepressants, danoxidazine, morphine, somatrazine marijuana, nicotine, phenytoin, epinephrine.

Beta-blockers, reserpine, octreotide, pentamidine can both increase and decrease the hypoglycemic effect of insulin.

Concomitant use of beta-blockers, clonidine, guanethidine or reserpine may mask the symptoms of hypoglycemia.

Pharmaceutically incompatible with solutions of other drugs.